Denali Therapeutics CMO reports initial holdings

Q: How many Denali Therapeutics (DNLI) common shares does the CMO hold?

Peter Scott Chin reports direct ownership of 170,612 common shares. This total includes 2,326 shares acquired under the Denali ESPP and a substantial portion represented by 145,845 unvested RSUs granted as part of his compensation package.

Q: What unvested RSUs does the Denali Therapeutics (DNLI) CMO report?

The filing states that Peter Scott Chin holds 145,845 unvested RSUs. These restricted stock units generally convert into common shares over time, subject to vesting schedules tied to continued employment and, in some cases, performance conditions set by the company.

Q: What stock options are reported by the Denali Therapeutics (DNLI) CMO?

The CMO reports several stock options to buy Denali common stock, including options over 63,800 shares at $20.17 and 40,650 shares at $21.26, with expirations between 2029 and 2036. These options form a key part of his long-term incentives.

Q: Are the Denali Therapeutics (DNLI) CMO’s options currently exercisable?

One option block is described as fully vested and exercisable, while others vest over time. Several options vest 25% on specific January dates, with the remaining shares vesting in 1/48 monthly installments, creating a gradual, long-term vesting profile.

Q: Does this Denali Therapeutics (DNLI) Form 3 indicate insider buying or selling?

No, this Form 3 is an initial statement of beneficial ownership. It lists existing holdings in common shares, RSUs, and options for the CMO. It does not report open-market buy or sell transactions in Denali Therapeutics stock.

Denali Therapeutics Inc. Chief Medical Officer Peter Scott Chin filed an initial ownership report showing direct holdings of 170,612 shares of common stock, including 2,326 shares acquired under the Denali ESPP and 145,845 unvested RSUs.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Denali Therapeutics Inc. Chief Medical Officer Peter Scott Chin filed an initial ownership report showing direct holdings of 170,612 shares of common stock, including 2,326 shares acquired under the Denali ESPP and 145,845 unvested RSUs. He also holds multiple fully vested or time-vesting stock options to buy common shares at exercise prices ranging from $20.17 to $80.03, with expirations extending through 2036. These positions reflect equity-based compensation typical for a senior executive and do not represent new market purchases or sales.

Insider Trade Summary

10 transactions reported

Mixed 10 txns

Insider Chin Peter Scott

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 297,700 contracts (Direct); Common Stock — 170,612 shares (Direct)

Footnotes (7)

F1. Includes 2,326 shares acquired under the Denali ESPP.
F2. Includes 145,845 Unvested RSU's.
F3. The shares subject to the option are fully vested and exercisable.
F4. 25% of the shares subject to the option vested on January 3, 2024 and an additional 1/48 of the shares vested monthly thereafter.
F5. 25% of the shares subject to the option vested on January 3, 2025 and an additional 1/48 of the shares vest monthly thereafter.
F6. 25% of the shares subject to the option vested on January 3, 2026 and an additional 1/48 of the shares vest monthly thereafter.
F7. 25% of the shares subject to the option will vest on January 3, 2027 and an additional 1/48 of the shares vest monthly thereafter.

Key Figures

Common shares held: 170,612 shares ESPP shares included: 2,326 shares Unvested RSUs: 145,845 units +4 more

7 metrics

Common shares held 170,612 shares Direct common stock holdings reported on Form 3

ESPP shares included 2,326 shares Shares acquired under the Denali ESPP

Unvested RSUs 145,845 units Unvested restricted stock units held by the CMO

Option block 1 63,800 shares at $20.17 Stock option exercise price and size, expires 2036-03-20

Option block 2 40,650 shares at $21.26 Stock option exercise price and size, expires 2035-01-03

Highest option strike $80.03 per share Exercise price on 14,250 underlying shares, expires 2031-01-10

Latest option expiry 2036-03-20 Final expiration date among reported stock options

Key Terms

Denali ESPP, Unvested RSU's, Stock Option (right to buy), fully vested and exercisable, +1 more

5 terms

Denali ESPP financial

"Includes 2,326 shares acquired under the Denali ESPP."

Unvested RSU's financial

"Includes 145,845 Unvested RSU's."

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

fully vested and exercisable financial

"The shares subject to the option are fully vested and exercisable."

vest monthly thereafter financial

"an additional 1/48 of the shares vest monthly thereafter."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 by Denali Therapeutics (DNLI) CMO report?

The Form 3 shows Chief Medical Officer Peter Scott Chin’s existing equity stake, including 170,612 common shares, unvested RSUs, and several stock option grants. It is an initial ownership statement, not a report of new share purchases or sales.

How many Denali Therapeutics (DNLI) common shares does the CMO hold?

Peter Scott Chin reports direct ownership of 170,612 common shares. This total includes 2,326 shares acquired under the Denali ESPP and a substantial portion represented by 145,845 unvested RSUs granted as part of his compensation package.

What unvested RSUs does the Denali Therapeutics (DNLI) CMO report?

The filing states that Peter Scott Chin holds 145,845 unvested RSUs. These restricted stock units generally convert into common shares over time, subject to vesting schedules tied to continued employment and, in some cases, performance conditions set by the company.

What stock options are reported by the Denali Therapeutics (DNLI) CMO?

The CMO reports several stock options to buy Denali common stock, including options over 63,800 shares at $20.17 and 40,650 shares at $21.26, with expirations between 2029 and 2036. These options form a key part of his long-term incentives.

Are the Denali Therapeutics (DNLI) CMO’s options currently exercisable?

One option block is described as fully vested and exercisable, while others vest over time. Several options vest 25% on specific January dates, with the remaining shares vesting in 1/48 monthly installments, creating a gradual, long-term vesting profile.

Does this Denali Therapeutics (DNLI) Form 3 indicate insider buying or selling?

No, this Form 3 is an initial statement of beneficial ownership. It lists existing holdings in common shares, RSUs, and options for the CMO. It does not report open-market buy or sell transactions in Denali Therapeutics stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/20/2026 - 07:22 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chin Peter Scott

(Last)

(First)

(Middle)

C/O DENALI THERAPEUTICS INC.

161 OYSTER POINT BOULEVARD, SECOND FLOOR

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/10/2026

3. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	170,612⁽¹⁾⁽²⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽³⁾	05/10/2029	Common Stock	43,000	$22.31	D
Stock Option (right to buy)	⁽³⁾	02/10/2030	Common Stock	35,100	$24.81	D
Stock Option (right to buy)	⁽³⁾	01/10/2031	Common Stock	14,250	$80.03	D
Stock Option (right to buy)	⁽³⁾	01/03/2032	Common Stock	13,000	$47.27	D
Stock Option (right to buy)	⁽³⁾	02/03/2032	Common Stock	10,250	$33.74	D
Stock Option (right to buy)	⁽⁴⁾	01/03/2033	Common Stock	32,900	$27.63	D
Stock Option (right to buy)	⁽⁵⁾	01/03/2034	Common Stock	44,750	$20.33	D
Stock Option (right to buy)	⁽⁶⁾	01/03/2035	Common Stock	40,650	$21.26	D
Stock Option (right to buy)	⁽⁷⁾	03/20/2036	Common Stock	63,800	$20.17	D

Explanation of Responses:

1. Includes 2,326 shares acquired under the Denali ESPP.

2. Includes 145,845 Unvested RSU's.

3. The shares subject to the option are fully vested and exercisable.

4. 25% of the shares subject to the option vested on January 3, 2024 and an additional 1/48 of the shares vested monthly thereafter.

5. 25% of the shares subject to the option vested on January 3, 2025 and an additional 1/48 of the shares vest monthly thereafter.

6. 25% of the shares subject to the option vested on January 3, 2026 and an additional 1/48 of the shares vest monthly thereafter.

7. 25% of the shares subject to the option will vest on January 3, 2027 and an additional 1/48 of the shares vest monthly thereafter.

Remarks:

	/s/ Tyler Nielsen, by power of attorney	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR